Lapatinib in combination with capecitabine is indicated for patients with HER2 who have previously received advanced or metastatic breast cancer including anthracycline, paclitaxel, and trastuzumab.
Lapatinib is a tyrosine kinase inhibitor that potently inhibits human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor receptor-2 (ErbB2) tyrosine kinase activity. It is unique in that it can work through multiple pathways so that breast cancer cells cannot receive the signals needed to grow.
|Appearance||Yellow crystalline powder|
|Appearance:||Yellow crystalline powder|
|Package details:||1kg/foil bag; 25kg/drum|
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!